Curatis Inks Japan Deal for Novel Brain Edema Drug, Offering Hope Beyond Steroids

LIESTAL, Switzerland & TOKYO – March 11, 2026

A landmark agreement between Swiss pharmaceutical company Curatis Holding AG and Japan’s Neupharma Co., Ltd. is set to introduce a promising new therapy for a debilitating complication of brain cancer to the Japanese market. The exclusive licensing deal, potentially worth up to CHF 83.5 million, grants Neupharma the rights to develop and commercialize corticorelin, a drug designed to treat peritumoral brain edema (PTBE) and offer a much-needed alternative to the harsh side effects of long-term steroid use.

A Crippling Condition, An Imperfect Solution

For thousands of patients with primary or metastatic brain tumors, the fight against cancer is compounded by a secondary, often devastating condition: peritumoral brain edema, or PTBE. This occurs when fluid accumulates in the brain tissue surrounding a tumor, leading to increased intracranial pressure. The resulting symptoms can be severe, ranging from debilitating headaches and vomiting to profound neurological dysfunction, including paralysis, speech loss, and altered mental states.

The current standard of care for managing this swelling is not a targeted therapy but a blunt instrument: high-dose corticosteroids like dexamethasone. While effective at reducing edema and providing temporary symptomatic relief, these steroids come at a significant cost to the patient's quality of life. Long-term use is associated with a litany of severe side effects, including severe muscle weakness (myopathy), impaired glucose metabolism that can lead to diabetes, gastrointestinal bleeding, osteoporosis, and significant personality changes.

Furthermore, the immunosuppressive nature of corticosteroids can directly interfere with modern cancer treatments. They can counteract the effectiveness of both chemotherapy and emerging immunotherapies that rely on a robust T-cell response, placing doctors and patients in a difficult position. With no approved targeted therapies for PTBE, a critical unmet medical need exists for the estimated 500,000 patients affected worldwide, including over 150,000 in the United States and approximately 60,000 in Japan.

Corticorelin: A Targeted Approach to Restore Quality of Life

Corticorelin, Curatis's lead drug candidate known as C-PTBE-01, represents a potential paradigm shift in managing PTBE. It is a synthetic version of a naturally occurring 41-amino acid polypeptide that has shown a unique ability to positively impact the blood-brain barrier after its disruption by a tumor. Unlike corticosteroids, which broadly suppress inflammation, corticorelin offers a more targeted mechanism.

The clinical data so far is promising. In studies involving patients with PTBE, corticorelin has demonstrated the potential to significantly reduce the required dose of steroids, and in some cases, replace them entirely. One double-blind study found that patients on corticorelin achieved a significantly greater reduction in their dexamethasone dose compared to a placebo group (62.7% vs. 51.4%). Patients in the corticorelin arm also showed improvements in myopathy and were less likely to develop the tell-tale signs of Cushing syndrome, a common side effect of long-term steroid use.

By offering a "steroid-sparing" effect, the drug aims to mitigate the debilitating side effects that often plague brain tumor patients, thereby dramatically improving their quality of life. The initial plan to introduce the therapy for children and adolescents in Japan is particularly significant, as this vulnerable population is especially susceptible to the long-term developmental and health consequences of high-dose steroid treatment.

The Strategic Value of an CHF 83.5 Million Partnership

The agreement between Curatis and Neupharma is a calculated strategic move for both companies, underscored by a significant financial commitment. Under the terms, Curatis is set to receive upfront and milestone payments that could total up to CHF 83.5 million, in addition to tiered royalties of up to 20% on future Japanese sales. This structure provides Curatis with non-dilutive funding to advance its pipeline while validating the commercial potential of its lead asset.

For Neupharma, the deal provides exclusive access to a first-in-class therapeutic for a condition with no approved treatments in its home market. The company, which specializes in bringing innovative drugs for rare and progressive diseases to Japan, will leverage its expertise to finance and conduct the pivotal clinical trial necessary for regulatory approval. This partnership allows Curatis to tap into the lucrative Japanese market by leveraging a local partner with a proven track record and deep understanding of the regulatory landscape.

The market opportunity is substantial. With a global market potential estimated to exceed USD 1 billion annually, securing a foothold in Japan—the world's third-largest pharmaceutical market—is a critical step. The financial terms of the deal reflect both the high unmet need for a PTBE therapy and the confidence both parties have in corticorelin's potential success.

Navigating Japan's Supportive Regulatory Landscape

This collaboration highlights a growing trend of Western biotech firms partnering with local experts to navigate Japan's unique and increasingly attractive pharmaceutical market. Japan's government has designated rare and intractable diseases a national priority, creating a highly supportive ecosystem for orphan drugs like corticorelin.

The Pharmaceuticals and Medical Devices Agency (PMDA), Japan's regulatory body, offers significant incentives, including priority reviews, extended market exclusivity (up to 10 years), and tax credits. This has resulted in a remarkably high success rate for orphan drug approvals in Japan, reportedly far exceeding that of the United States. Neupharma's role will be to steer corticorelin through this process, with a meeting with the PMDA planned for the summer of 2026 and the pivotal clinical study slated to begin in 2027.

While Neupharma focuses on the Japanese trial, Curatis has confirmed that its preparatory work for a pivotal Phase 3 study aimed at securing approval in the United States and Europe is proceeding as planned. This parallel-track approach demonstrates a comprehensive global strategy, positioning corticorelin to become a worldwide standard of care and transforming the treatment landscape for brain tumor patients everywhere.